Launch-iT
Technology
We have developed a best-in-class platform for virus-targeted immunotherapy
Durable effector and memory T-cells capable of clearing virus-infected cells
Tech transfer-ready and scalable manufacturing process
Broad applicability across major unmet medical needs in oncology and beyond
Introduction
Launch-iT proprietary platform
A unique platform combining today’s best technologies: plasmid DNA and self-amplifying viral vector.
Our clinically validated Launch-iT platform generates durable, antigen-specific T-cell responses that clear virus-infected cells, supported by a scalable, tech-transfer–ready manufacturing process.
A unique platform combining today’s best technologies: plasmid DNA + self-amplifying viral vector
Launch-iT proprietary platform - Process steps
Plasmid DNA
Standard administration by injection
Plasmid encoding for live-attenuated yellow fever vector with target antigen sequence
Self-amplifying viral vector
Spontaneous formation of self-amplifying yellow fever viral vectors containing the target antigen sequence and the produced target antigen
Broad immune response
Induction of antigen-specific effector and memory T cells capable of clearing cells infected with the target pathogen
Do not copy or distribute without permission of Astrivax
Discover more about our Launch-iT platform
Broad applicability across major unmet medical needs in oncology and beyond
Broad applicability across major unmet medical needs in oncology and beyond
Lorem ipsum
Tech transfer-ready and scalable manufacturing process
Tech transfer-ready and scalable manufacturing process
Lorem Ipsum
Durable effector and memory T-cells capable of clearing virus-infected cells
Durable effector and memory T-cells capable of clearing virus-infected cells
Lorem ipsum dolor sit amet. Est incidunt quaerat sit ipsam omnis et similique distinctio eum amet facere sed blanditiis magnam. In rerum adipisci quo lLorem ipsum dolor sit amet. Est incidunt quaerat sit ipsam omnis et similique distinctio eum amet facere sed blanditiis magnam. In rerum adipisci quo lLorem ipsum dolor sit amet.
Broad applicability across major unmet medical needs in oncology and beyond
Lorem ipsum
Tech transfer-ready and scalable manufacturing process
Lorem Ipsum
Durable effector and memory T-cells capable of clearing virus-infected cells
Lorem ipsum dolor sit amet. Est incidunt quaerat sit ipsam omnis et similique distinctio eum amet facere sed blanditiis magnam. In rerum adipisci quo lLorem ipsum dolor sit amet. Est incidunt quaerat sit ipsam omnis et similique distinctio eum amet facere sed blanditiis magnam. In rerum adipisci quo lLorem ipsum dolor sit amet.
Download our latest poster here:
NOVEL IMMUNOTHERAPY GENERATES ROBUST HPV-SPECIFIC T-CELL RESPONSES AND SHOWS EFFICACY IN A HPV16 TUMOR MODEL
Bringing virus-targeted immunotherapy to patients
Contact